New drug combo shows promise in shrinking aggressive breast tumors before surgery
NCT ID NCT04126525
First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 32 times
Summary
This study tests whether adding the targeted drug pyrotinib to standard chemotherapy and trastuzumab before surgery can completely eliminate tumors in women with early-stage HER2-positive breast cancer. About 53 women with stage II to III breast cancer will receive the combination, then have surgery to check for any remaining cancer. The goal is to improve the chance of a complete response, which may lead to better long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER FEMALE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Renji Hospital
Shanghai, China
Conditions
Explore the condition pages connected to this study.